Startups
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Drug development requires solid funding. Here’s who’s standing on higher ground this week with fresh investment dollars.
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
Thanks to a recent joint venture, there is a new company taking on cancer and autoimmune diseases.
Two different companies, cardiac fibrosis RNA company HAYA Therapeutics and COVID-19 bispecific player RenBio, launched today with funding rounds designed to push them toward the clinic.
Forbes highlights its “30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.
Three companies on different continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
The robust $77 million Series A was led by Octagon Capital and the leadership and research team behind the original Vedere Bio.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
PRESS RELEASES